Glenmark gets CDSCO panel nod to manufacture and market COPD drug

New Delhi: Based on the justification provided by the pharmaceutical major Glenmark pharmaceuticals, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has given its nod to manufacture and market the fixed dose combination (FDC) drug containing Indacaterol (as acetate) and Mometasone furoate Dry Powder for Inhalation (DPI) in Capsules.However,...
New Delhi: Based on the justification provided by the pharmaceutical major Glenmark pharmaceuticals, the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has given its nod to manufacture and market the fixed dose combination (FDC) drug containing Indacaterol (as acetate) and Mometasone furoate Dry Powder for Inhalation (DPI) in Capsules.
The committee noted that the drug is already approved by Europe, Australia, Canada, and Japan.